Amgen (NASDAQ:AMGN) Stock Quotes and News

185.99 -0.52 (-0.28%)

After Hours 185.99 (%)

Data as of Jun 21, 2018

Prev. Close 186.51
Price Open 186.51
Volume 2,103,969
Day's Range 184.415 - 186.51
52 Wk Range 162.69 - 201.23
50 Day Moving Avg. 176.48
PE Ratio 59.107937
Shares Outstanding 661.71M
Market Cap 123.07B

Trade AMGN stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
4/25/18	Morgan Stanley	Maintains	OverweightOverweight	200.0
4/05/18	Barclays	Maintains	Equal-WeightEqual-Weight	180.0
2/05/18	Atlantic Equities	Downgrades	OverweightNeutral

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO Label Benzinga NewsdeskTue, 19 Jun 2018 09:00:42 -0400
Health Canada Has Approved Amgen's Repatha For Treatment Of Cardiovascular Events In Adults With Atherosclerotic Cardiovascular Disease luke@benzinga.comTue, 19 Jun 2018 08:24:42 -0400
Amgen Announces FDA Approval Of Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS (carfilzomib) Label Benzinga NewsdeskMon, 11 Jun 2018 09:01:31 -0400
Amgen Announces European Commission Approval Of Prolia (denosumab) For Patients With Glucocorticoid-Induced Osteoporosis Benzinga NewsdeskFri, 08 Jun 2018 09:02:51 -0400
Amgen Reports Co.'s First Public-Private Partnership With Oklahoma Health Care Authority, Pharmacy Mgmt. Consultants Benzinga NewsdeskWed, 06 Jun 2018 16:02:33 -0400
Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index Shanthi RexalineTue, 05 Jun 2018 08:05:20 -0400
Amgen Shares Down 1.5% After Hours Following FDA Approval Of First Biosimilar To Neulasta, Mylan's Fulphila Benzinga NewsdeskMon, 04 Jun 2018 16:54:39 -0400
Amgen Reports Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS Extended Progression-Free Survival Vs A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma Eddie StaleyFri, 01 Jun 2018 16:01:41 -0400
EMA Has Recommended Approval Of Amgen, Novartis Migraine Drug Erenumab Paul QuintaroFri, 01 Jun 2018 07:28:40 -0400
Amgen, MD Anderson Report Collaboration To Accelerate Early-Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Other Cancers Paul QuintaroThu, 31 May 2018 16:00:46 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label PRNewswire2 days ago
Research Report Identifies Avangrid, Entercom Communications, Kennedy-Wilson, Emerson Electric, Amgen, and vTv Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement Globe NewswireJun 12, 2018
FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label PRNewswireJun 11, 2018
European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis PRNewswireJun 08, 2018
Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference PRNewswireJun 07, 2018
Amgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes PRNewswireJun 06, 2018
Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma PRNewswireJun 01, 2018
Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers PRNewswireMay 31, 2018
deCODE genetics Reveals: The Making of a Human Population Uncovered Through Ancient Icelandic Genomes PRNewswireMay 31, 2018
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment PRNewswireMay 23, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Neon Therapeutics Firms Its Plan For $100 Million IPO Seeking Alpha2 hours ago
Amgen Should Rebound On Aimovig And Kyprolis Revenue Seeking Alpha1 day ago
EC grants full approval for Amgen's Blincyto Seeking Alpha2 days ago
Teva to Discontinue a Fremanezumab Study on Cluster Headache Zacks3 days ago
Amgen's Neulasta Has a New Competitor GuruFocus4 days ago
Brief Mid-Year Update On 2018 Global Asset Allocation Seeking Alpha6 days ago
FDA OKs Mylan and Biocon's generic Neulasta Seeking AlphaJun 14, 2018
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA ZacksJun 14, 2018
Allergan (AGN) Presents Positive Data on Glaucoma Candidate ZacksJun 14, 2018
Autolus Therapeutics Readies $125 Million U.S. IPO Seeking AlphaJun 14, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q1 2018	EST	Actual	Surprise
EPS:	3.22	3.47	0.25
Rev:	5.41B	5.55B	144.00M

Q2 2018	EST	Actual	Surprise
EPS:	Expected 2018-07-24
Rev:	Expected 2018-07-24

Company Profile

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Amgen Inc. AMGN:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Amgen Inc. AMGN:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners